(When the shoe was on the other foot, Abbott asked for a compulsory license, while criticizing Thailand for issuing compulsory licenses) On the 12th of January 2007, Abbott Laboratories lost a bid in a U.S. District Court (the Western District… Continue Reading
Michel Lotrowska, a musician and health activist in Brazil, posted this informative note on Brazil’s latest announcement that it was considering a compulsory license on patents for a medicine — in this case, efavirenz, the BMS/Merck AIDS drug marketed by… Continue Reading
On Friday, March 16, KEI organized a briefing in the U.S. Capitol on Thailand’s recent compulsory licenses on three drugs; two for HIV/AIDS (Merck’s efavirenz (Stocrin) and Abbott’s lopinavir + ritonavir (Kaletra)) and one for heart disease (Sanofi’s clopidogrel (Plavix)). … Continue Reading
March 2, 2007 Secretary of the Expert Committee on the Selection and Use of Essential Medicines (2007)Department of Medicines Policy and Standards (PSM)Health Technology & PharmaceuticalsWorld Health OrganizationCH-1211 Geneva 27Switzerland Via e-mail: emisecretariat@who.int RE: Request for changes in the WHO Model… Continue Reading
The following is the text of a letter to Dr. Margaret Chan, Director-General Elect, World Health Organization (WHO), asking for a review of the Essential Drugs List (EDL) as it relates to patented products. Consumer Project on Technology http://www.cptech.org December… Continue Reading
Here is a link to the text of the WHO EB’s draft resolution on the resport of the WHO Commission on Intellectual Property, Innovation and Public Health (CIPIH). http://www.cptech.org/ip/health/who/WHOcipih280406.html from the mini EB meeting on April 28. The US government… Continue Reading
Original page: http://www.cptech.org/ip/wto/p6/eu12052005.pdf Letter from CPTech referenced available here: https://www.keionline.org/32641 MARKOS KYPRIANOU PETER MANDELSON Member of the European Commission … Continue Reading
This is a joint statement by that NGOs presented to negotiators in 2005, as the WTO considered an amendment on TRIPS and public health, to address cases where medicines would be exported to countries with “insufficient or no manufacturing capacity.”… Continue Reading
Original page: http://www.cptech.org/ip/health/tamiflu/christinelagarde.html Christine LAGARDE asked to change EU “opt-out” of 30 August 2003 decision regarding imports of generic medicines manufactured under a compulsory license To: Christine LAGARDE, Ministre déléguée au Commerce extérieur, France From: Manon Ress and James Love,… Continue Reading
Original page: http://www.cptech.org/ip/health/tamiflu/cptech-mandelson10192005.html CPTech Letter to EC Director General of Trade Peter Mandelson 19th October 2005 Commissioner Mandelson EUROPEAN COMMISSION DG Trade 200 rue de la Loi B-1049 BRUSSELS Dear Commissioner Mandelson TRIPS Agreement and Avian Influenza We ask the… Continue Reading